Table 5 Comparison of clinicopathological features in DHL/THL and DLBCL cases.
DHL/THL (57) | DLBCL (57) | p | |
|---|---|---|---|
Age, mean (range), years | 51.8 (19.0–82.0) | 59.1 (23–91) | 0.008 |
Sex: no. (%) | |||
Female | 23 (40.4) | 27 (47.4) | 0.450 |
Male | 34 (59.6) | 30 (52.6) | |
History, median (range), months | 1.0 (0.25–34.0) | 2.0 (1.0–36.0) | 0.566 |
B symptoms: no. (%) | |||
Yes | 20 (38.5) | 12 (21.1) | 0.046 |
No | 32 (61.5) | 45 (78.9) | |
NA | 5 | 0 | |
Stage: no. (%) | |||
I/ II | 15 (28.9) | 23 (40.3) | 0.208 |
III/ IV | 37 (71.1) | 34 (59.7) | |
NA | 5 | 0 | |
CNS involvement: no. (%) | |||
Yes | 4 (8.9) | 0 (0) | 0.075 |
No | 41 (91.1) | 57 (100) | |
NA | 12 | 0 | |
Bone marrow involvement: no. (%) | |||
Yes | 3 (6.5) | 0 (0) | 0.172 |
No | 43 (93.5) | 57 (100) | |
NA | 11 | 0 | |
Hans classification: no. (%) | |||
GCB | 37 (64.9) | 22 (38.6) | 0.005 |
Non-GCB | 20 (35.1) | 35 (61.4) | |
IPI score: no. (%) | |||
<3 | 23 (50.0) | 32 (56.1) | 0.535 |
≥3 | 23 (50.0) | 25 (43.9) | |
NA | 11 | 0 | |
DEL | |||
Yes | 33 (57.9) | 21 (36.8) | 0.024 |
No | 24 (42.1) | 36 (63.2) | |
LDH, median (range), U/L | 272.1 (122.6–2617) | 216 (106–1598) | 0.149 |
HBV infection status | |||
NHHI | 24 (48.0) | 43 (75.4) | 0.003 |
PHI | 26 (52.0) | 14 (24.6) | |
NA | 7 | 0 | |
Follow-up | |||
AWD | 35 (64.8) | 48 (84.2) | 0.019 |
DOD | 19 (35.2) | 9 (15.8) | |
LFU | 3 | 0 | |
Median follow-up in months (range) | 17 (1–43) | 24 (1–65) | 0.016 |
Immunophenotype | |||
CD10 | |||
Positive | 35 (61.4) | 20 (35.1) | 0.005 |
Negative | 22 (38.6) | 37 (64.9) | |
BCL6 | |||
Positive | 51 (89.5) | 50 (87.7) | 0.768 |
Negative | 6 (10.5) | 7 (12.3) | |
Mum-1 | |||
Positive | 29 (51.8) | 43 (75.4) | 0.009 |
Negative | 27 (48.2) | 14 (24.6) | |
NA | 1 | 0 | |
BCL2 | |||
Positive | 44 (80.0) | 45 (78.9) | 0.890 |
Negative | 11 (20.0) | 12 (21.1) | |
NA | 2 | 0 | |
Ki-67 (%), median (range) | 90 (30–98) | 80 (20–90) | 0.024 |
MYC (%), median (range) | 70 (0–100) | 30 (0–85) | <0.001 |
